Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
New Discovery May Benefit Farmers Worldwide
Scientists have shown how a crop-microbe 'team' protect against fungal infection.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Scroll Up
Scroll Down

Social Media in the Pharmaceutical Industry
Bookmark and Share


Astra Zeneca

Two primary themes are captured in the paper:

1. Social media is a fundamental part of advancing public health.

2. Pharmaceutical companies have a responsibility to engage more fully in social media.

The paper includes the thoughts of patients, health advocates, former government officials, bloggers and others who participated in a roundtable discussion that AstraZeneca convened late last year. The discussion, which was facilitated by members of Google’s Health Industry Team, sought specific feedback on AstraZeneca’s social media principles – and included considerable discussion on the social media guidelines expected to be released by the FDA later this year.

It summarises and addresses key discussion points that arose from both the Social Media Roundtable and DPE, as well as several considerations for the FDA in its development of social media guidance.

In the paper, Astrazeneca put forth five principles required for appropriate pharmaceutical manufacturer engagement in social media.

The white paper says the FDA should engage with the pharmaceutical industry to help them research and resolve issues raised by social media.

Further Information

Related Content

30 to 40 % of Mental Illnesses in UAE are Schizophrenia-related
Catatonic schizophrenia disappeared from the UAE thanks to the country’s advanced healthcare practices
Thursday, October 29, 2009
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!